Skip to main content
. 2004 Dec 31;115(1):132–138. doi: 10.1016/j.jaci.2004.09.025

Table III.

Treatments prescribed for cases and controls

Cases
Controls
n (%) n (%) P
Prescribed β2 agonist 43/57 (75.4) 148/157 (94.3) <.001
Prescribed inhaled corticosteroids 28/57 (49.1) 133/157 (84.7) <.001
Prescribed leukotriene receptor antagonist 5/57 (8.8) 32/157 (20.4) .04
Prescription coverage 46/57 (80.7) 133/157 (84.7) NS
Mite-impervious mattress cover 1/54 (1.9) 32/157 (20.4) .004